Treats clinically important hypotension occurring in the setting of anesthesia. ANDA 218271, held by Fresenius Kabi USA. Ephedrine Sulfate.
As of Nov 16, 2026, ANDA 218271 (Ephedrine Sulfate), held by Fresenius Kabi USA, was first approved by FDA on Mar 11, 2025, with 0 approved supplements and 0 published complete response letters.
Ephedrine Sulfate Injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 11, 2025 | Original application | Approved | None posted |
| Ephedrine Sulfate25MG/5ML (5MG/ML) · solution;intravenous | Ephedrine Sulfate | Rx |
| Ephedrine Sulfate50MG/10ML (5MG/ML) · solution;intravenous | Ephedrine Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters